Related Experiment Video
Updated: Jan 24, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer
Abstract:
For the use of immunotherapy in metastatic non-small cell lung cancer (NSCLC), the NCCN Guidelines for NSCLC reflect the importance of assessing levels of PD-L1 expression to determine the best use of PD-1/PD-L1 inhibitors, whether alone or in combination with chemotherapy. Patients who lack a driver mutation and have tumor PD-L1 expression ≥50% are recommended to receive single-agent pembrolizumab, although combining with carboplatin/pemetrexed is also a reasonable choice, especially if there is higher burden of disease. For tumors with PD-L1 expression <50%, it is important to distinguish between nonsquamous and squamous cell carcinoma (SCC). For patients with non-SCC disease, pembrolizumab + carboplatin/pemetrexed is preferred. Alternately, a 4-drug regimen of carboplatin/paclitaxel/bevacizumab/atezolizumab is reasonable, especially for patients ineligible for pemetrexed. In patients with SCC, carboplatin + paclitaxel or nab-paclitaxel with pembrolizumab is a category 1 recommendation. Tumor mutational burden is emerging as a biomarker for efficacy but is not yet ready to be used in patient selection. Optimal management of the unique toxicities associated with immunotherapy, which can be more frequent with these combinations, is also critical for good outcomes.
Insights
NCCN guidelines for metastatic non-small cell lung cancer (NSCLC) emphasize PD-L1 testing for immunotherapy. Treatment selection depends on PD-L1 levels and cancer subtype, guiding choices for PD-1/PD-L1 inhibitors.
Area of Science:
- Oncology
- Pulmonology
- Immunotherapy
Background:
- NCCN guidelines for metastatic non-small cell lung cancer (NSCLC) incorporate PD-L1 expression levels to guide immunotherapy selection.
- PD-1/PD-L1 inhibitors are crucial, used alone or with chemotherapy based on patient and tumor characteristics.
Discussion:
- For patients with PD-L1 expression ≥50% and no driver mutation, single-agent pembrolizumab is recommended, with combination therapy as an option for high disease burden.
- Treatment strategies diverge for PD-L1 <50% NSCLC based on histology: non-squamous cell carcinoma (SCC) favors pembrolizumab plus carboplatin/pemetrexed, while SCC recommends carboplatin/paclitaxel with pembrolizumab.
Key Insights:
- PD-L1 expression thresholds (≥50% vs. <50%) and tumor histology (squamous vs. non-squamous) are critical determinants for immunotherapy selection in NSCLC.
- Combination regimens like pembrolizumab plus chemotherapy or multi-drug options (e.g., carboplatin/paclitaxel/bevacizumab/atezolizumab) offer alternatives, especially for specific patient groups or pemetrexed ineligibility.
- Emerging biomarkers like tumor mutational burden show promise but are not yet standard for patient selection.
Outlook:
- Continued research into biomarkers like tumor mutational burden may refine immunotherapy selection in NSCLC.
- Management of immunotherapy-related toxicities is essential for optimizing patient outcomes with these advanced treatment regimens.
Related Concept Videos
01:11Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
01:18Guidelines and Strategies for Safe Computer Charting
Maintain Confidentiality and Security:
01:27Tumor Immunotherapy
01:26Guidelines for Nursing Documentation II
Timely documentation is crucial to ensure continuity of care for patients. Any delays in recording or reporting medical information can result in medical errors and even adverse patient outcomes. From medication administration to diagnostic test results, every detail must be accurately and promptly documented to provide the best possible care for patients.
01:06Legal Guidelines for Documentation
02:24Predicting Reaction Outcomes